Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results

Çakir, Akın; Erden, Burak; Bölükbaşı, Selim; Sever, Ozkan; Erkul, Sezin Ozdogan; Osmanbaşoğlu, Özen Ayrancı; Karaca, Gulderen; Elçioğlu, Mustafa Nuri

doi:10.5935/0004-2749.20200078

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All participants received intravitreal injections of conbercept (0.5 mg/0.05 mL) following a 3 + pro re nata (PRN) regimen (16)(17)(18), administered under aseptic conditions. This regimen consisted of one injection per month for the first 3 months,…”

Section: Treatmentmentioning

confidence: 99%

Efficacy and safety of intravitreal injection of conbercept for moderate to severe nonproliferative diabetic retinopathy

Shen,

Zheng,

Gao

et al. 2024

Front. Med.

View full text Add to dashboard Cite

PurposeThis study aimed to assess the effectiveness and safety of intravitreal injection of conbercept (IVC) in treating moderate to severe nonproliferative diabetic retinopathy (NPDR), with or without accompanying diabetic macular edema.MethodsIn this longitudinal retrospective study, 35 patients (50 eyes) with moderate to severe NPDR and Diabetic Retinopathy Severity Scale (DRSS) scores between 43 and 53 were treated at the Department of Ophthalmology, First Affiliated Hospital of Kunming Medical University, from October 2018 to January 2023. Treatment protocol included three monthly IVC injections followed by a pro re nata (PRN) regimen over a two-year follow-up period. Outcome measures were best-corrected visual acuity (BCVA), intraocular pressure, central macular thickness (CMT), extent of hard exudate (HE), and changes in DRSS scores. DRSS scores before and after treatment were analyzed using the Wilcoxon rank-sum test. Both systemic and ocular adverse events were meticulously documented to ascertain safety.ResultsFrom baseline to the final follow-up, the mean BCVA improved from 0.41 ± 0.39 to 0.23 ± 0.20 logMAR (p<0.05). The mean CMT decreased from 306.22 ± 77.40 to 297.97 ± 88.15 μm (p = 0.385). At 24 months, DRSS scores improved by ≥1 stage in 40 eyes (80%), ≥ 2 stages in 28 eyes (56%), ≥3 stages in 10 eyes (20%), and remained stable in 6 eyes (12%). The DRSS scores at each follow-up interval demonstrated statistically significant improvement from baseline (p<0.05). In 15 of 27 eyes (55.56%) with diabetic macular edema (DME), there was a significant reduction in the mean area of HE from baseline (p<0.05). No serious systemic adverse events were observed.ConclusionIVC is an effective and safe treatment for moderate to severe NPDR, demonstrating significant improvements in DRSS scores.

show abstract

Section: Treatmentmentioning

confidence: 99%

Efficacy and safety of intravitreal injection of conbercept for moderate to severe nonproliferative diabetic retinopathy

Shen,

Zheng,

Gao

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?

Ozsaygılı,

Bayram

2024

Int Ophthalmol

View full text Add to dashboard Cite

To compare the anatomical and functional outcomes of the combination of a ibercept and dexamethasone implant (CT) against a ibercept monotherapy (AM) in treatment-naive diabetic macular edema (DME) patients with serous macular detachment and hyperre ective foci. MethodsThis study included 82 eyes of 82 patients with treatment-naive DME who completed the follow-up period of 12 months. All patients had optical coherence tomography (OCT) biomarkers of an in ammatory DME phenotype. Patients were consecutively selected and classi ed into two groups. The CT group consisted of 39 eyes treated with a ibercept therapy and initially combined with a single-dose dexamethasone implant. The AM group consisted of 43 eyes treated with a ibercept alone. The primary outcome measures of the study were the mean reduction of the central macular thickness (CMT) and total macular volume parameters (TMV) and improvement in best-corrected visual acuity (BCVA). ResultsIn both groups, the patient characteristics including age, gender, duration of diabetes, HbA1c levels, phakic percentage, and diabetic retinopathy status were similar (P > 0.05). The mean reduction in CMT and TMV was signi cantly higher in the CT group compared to the AM group (P < 0.001 and P = 0.002, respectively), while mean letter gains were not signi cantly higher (P = 0.240) at the end of the study. In the CT group, 8 eyes (20.5%) showed a transient IOP increase, and 18% of patients developed cataract. In subgroup analysis, the mean letter gain in pseudophakic eyes was signi cantly higher (12.5 in the CT vs. 9.3 in the AM group, P = 0.027). ConclusionThe CT, where in ammation is prominent, can provide faster recovery. The pseudophakic eyes seem to be the ideal patient group for CT.

show abstract

Résultats anatomiques et fonctionnels du protocole thérapeutique « 3 + PRN » dans le traitement de l’œdème maculaire diabétique

Ammari,

Chaabene,

Messaoud

2024

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results

Cited by 4 publications

References 0 publications

Efficacy and safety of intravitreal injection of conbercept for moderate to severe nonproliferative diabetic retinopathy

Efficacy and safety of intravitreal injection of conbercept for moderate to severe nonproliferative diabetic retinopathy

Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?

Résultats anatomiques et fonctionnels du protocole thérapeutique « 3 + PRN » dans le traitement de l’œdème maculaire diabétique

Contact Info

Product

Resources

About